Clinical Study for the Regress of CIN1/CIN2 by Highly Effective DC Vaccines Targeting HPV 16/18 E6/ E7 Protein

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900021871

Enrollment

Unknown

Registered

2019-03-13

Start date

2019-04-01

Completion date

Unknown

Last updated

2019-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Intraepithelial Neoplastic

Interventions

Case series:DC vaccines targeting HPV 16/18 E6/ E7 protein and DC vaccine would be injected to patients once a week, six doses in total.

Eligibility

Sex/Gender

Female

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: nclusion Criteria: ? Aged 18 to 70 years at the time of informed consent ? HPV type 16/18 positive ? Pathologically confirmed CIN1/2 and no other cervical disease ? adequate organ functions.

Exclusion criteria

Exclusion criteria: Exclusion Criteria: ? Severe allergy to drugs ? Women of child-bearing potential who are pregnant or breast-feeding ? Any form of primary immunodeficiency ? With serious cardiac, cerebrovascular and primary diseases ? With a history of severe mental illness

Design outcomes

Primary

Measure	Time frame
Safety of neoantigen-primed DC cells Vaccine;mmunogenicity of a neoantigen-primed DC cell Vaccine;Objective Response Rate;	—

Countries

China

Contacts

Public ContactLili Ren

Shenzhen People's Hospital

ren.lili@szhospital.com+86 0755 22942466

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026